{"slideshow_credits": null, "snippet": "Palbociclib, a drug being developed by Pfizer, sharply cut the risk that advanced cancer would worsen among patients taking part in a Phase 2 study, researchers said.", "abstract": "Researchers say palbociclib, new type of drug being developed by Pfizer, cut in half the risk that advanced breast cancer would worsen among patients taking part in a Phase 2 study; drug potentially provides important new treatment option for women and blockbuster product for Pfizer.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/04/07/business/breast-cancer-drug-shows-groundbreaking-results.html", "lead_paragraph": "Palbociclib, a drug being developed by Pfizer, sharply cut the risk that advanced cancer would worsen among patients taking part in a Phase 2 study, researchers said.", "headline": {"main": "Guarded Optimism After Breast Cancer Drug Shows Promising Results", "print_headline": "Guarded Optimism After Breast Cancer Drug Shows Promising Results"}, "_id": "5341652f38f0d834c5bbfec5", "word_count": "976", "multimedia": [], "pub_date": "2014-04-07T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "American Assn for Cancer Research", "name": "organizations", "is_major": "N", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Finn, Richard S", "name": "persons", "is_major": "N", "rank": "6"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Breast Cancer", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Pfizer Inc", "name": "organizations", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}